Company

Zucara Therapeutics Inc.

Vancouver-based biotech developing ZT-01, a once-daily treatment to prevent hypoglycemia in people with Type 1 diabetes.

About

Founded in 2015 and headquartered in Vancouver, Canada, Zucara Therapeutics Inc. is developing ZT-01, which blocks somatostatin type 2 receptors in the pancreas to restore glucagon production and counter low blood sugar. Richard Liggins is the founder and Michael Midmer is CEO. In May 2025 the company raised USD 5 million in series B funding from returning investor JDRF T1D Fund, with other unspecified investors also participating.

6Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in